DEFA14A: Novartis to Acquire Avidity Biosciences for $12 Billion

Novartis AG plans to acquire Avidity Biosciences for $12 billion, with Avidity spinning off its early-stage precision cardiology programs into a new independent entity, SpinCo.

Summary

• Novartis AG, through its indirect wholly owned subsidiary Ajax Acquisition Sub, Inc. (Merger Sub), will acquire Avidity Biosciences, Inc. (Avidity).
• The proposed acquisition is valued at $12 billion, as announced on October 26, 2025.
• Prior to the merger, Avidity will undergo a pre-closing reorganization, spinning off its early-stage precision cardiology programs and certain collaboration agreements into a newly formed, wholly-owned subsidiary, Bryce Therapeutics, Inc. (to be renamed SpinCo).
• Following the reorganization, Avidity will either distribute SpinCo Common Stock to its stockholders on a pro rata basis (1 share of SpinCo per 10 shares of Avidity common stock) or sell SpinCo to a third party.
• After the spin-off, Avidity will have no continuing ownership interest in SpinCo, which will operate as a separate and independent company.
• The Agreement and Plan of Merger and the Separation and Distribution Agreement were both dated October 25, 2025.
• The acquisition is expected to close in the first half of 2026.
• Avidity's late-stage programs, including those targeting Duchenne muscular dystrophy, myotonic dystrophy type 1 (DM1), and FSHD, are anticipated to benefit from Novartis's global development and commercialization expertise post-acquisition.

Sentiment

Score: 9

Explanation: The filing announces a major acquisition by Novartis for $12 billion, which is a highly positive event for Avidity Biosciences and its shareholders. The spin-off also provides continued exposure to early-stage assets. While there are standard risks associated with mergers and R&D, the overall sentiment is overwhelmingly positive due to the significant valuation and strategic validation.

Positives

• Avidity Biosciences is being acquired by Novartis for a significant valuation of $12 billion, representing a substantial return for shareholders.
• The acquisition validates Avidity's Antibody Oligonucleotide Conjugates (AOCs) platform and its potential for developing life-changing therapies for muscle-wasting diseases.
• Avidity's late-stage programs for Duchenne muscular dystrophy, myotonic dystrophy type 1 (DM1), and FSHD will gain access to Novartis's global development and commercialization expertise, potentially accelerating their path to market.
• The spin-off of early-stage precision cardiology programs into SpinCo allows Avidity stockholders to retain exposure to these assets as an independent entity.
• The deal highlights the success of venture philanthropy, with CureDuchenne's early investment of $26 million catalyzing over $3 billion in follow-on funding.

Negatives

• Avidity will cease to exist as an independent publicly traded company, becoming an indirect wholly-owned subsidiary of Novartis.
• Existing Avidity stockholders will no longer have direct ownership in Avidity's core business post-merger, instead receiving SpinCo shares or proceeds from its sale.
• The spin-off includes assets that trigger a right of first negotiation with an existing collaboration partner, which could introduce complexities for SpinCo's future.

Risks

• The timing of the satisfaction of customary closing conditions, including regulatory approvals and Avidity stockholder approval, may not occur on the expected timetable or at all.
• Risks and costs related to the implementation of the SpinCo separation, including the ability to complete it in the anticipated timeframe or at all, and potential changes to the configuration of businesses included in the separation.
• The sale of certain of SpinCo's assets pursuant to a third-party right of first negotiation.
• The risk that competing offers or acquisition proposals for Avidity will be made.
• Disruption from the transactions and the impact of the announcement and pendency on Novartis's and Avidity's businesses, including relationships with employees, business partners, or governmental entities.
• The risk that the transactions may be more expensive to complete than anticipated.
• The risk that stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Diversion of management's attention from ongoing business operations and opportunities due to the transactions.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.
• There is no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.
• There is no guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.
• There is no guarantee that the expected benefits or synergies from the transactions will be achieved in the expected timeframe, or at all.

Future Outlook

The acquisition is expected to accelerate the development and commercialization of Avidity's late-stage programs for muscle-wasting diseases, leveraging Novartis's global expertise. The spin-off of early-stage cardiology programs into SpinCo aims to create a separate, independent company. The acquisition is anticipated to close in the first half of 2026.

Management Comments

• "We are incredibly grateful to CureDuchenne for their early and long-standing belief and support of Avidity. Close collaboration with patient advocacy organizations has been absolutely critical to our scientific and clinical success, and I remain confident in the tremendous potential of our groundbreaking investigational treatments as Avidity prepares for the proposed acquisition by Novartis in the first half of 2026." Sarah Boyce, CEO, Avidity Biosciences.

Industry Context

This acquisition highlights a trend of large pharmaceutical companies acquiring innovative biotechnology firms with promising platforms, especially in areas with high unmet medical needs like rare muscle-wasting diseases. The deal also validates the venture philanthropy model, where patient advocacy groups provide early-stage funding to accelerate scientific breakthroughs, demonstrating its potential to generate significant returns and further research. Novartis's entry into the Duchenne therapeutic landscape with Avidity's late-stage programs could intensify competition and accelerate the availability of new therapies.

Comparison to Industry Standards

• The $12 billion acquisition price for a company with a platform technology and late-stage clinical programs, but no approved products, suggests a premium valuation, reflecting the high potential of Avidity's AOC platform and pipeline.
• The spin-off of early-stage assets is a common strategy in large M&A deals to streamline the acquiring company's focus and allow existing shareholders to retain value in non-core assets.
• CureDuchenne's investment of $26 million catalyzing over $3 billion in follow-on funding demonstrates a highly successful venture philanthropy model, exceeding typical returns seen in early-stage biotech investments.

Legal Proceedings

• Stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Avidity stockholders will receive consideration for their shares in the acquisition and potentially shares in SpinCo, representing a significant return on investment.
• Employees: The merger could lead to integration challenges or opportunities within Novartis, while SpinCo will form a new independent company with its own management team.
• Patients (Duchenne, DM1, FSHD): The acquisition by Novartis is expected to accelerate the development and commercialization of Avidity's late-stage therapies, potentially bringing life-changing treatments closer to patients.
• Collaboration Partners: The spin-off includes assets triggering a right of first negotiation with an existing collaboration partner, which could impact future relationships or asset control.

Next Steps

• Avidity, Novartis, and SpinCo intend to file relevant documents with the SEC, including preliminary and definitive proxy statements.
• The definitive proxy statement and proxy card will be delivered to Avidity stockholders for a special meeting related to the transactions.
• Avidity stockholders will vote on the proposed transactions.
• Completion of the pre-closing reorganization for the Spin-Off.
• Distribution of SpinCo Common Stock to Avidity stockholders or sale of SpinCo to a third party.
• Satisfaction of customary closing conditions, including regulatory approvals.
• Completion of the merger, expected in the first half of 2026.

Key Dates

Recommendation

The proposed $12 billion acquisition by Novartis represents a substantial premium and strong validation of Avidity's technology and pipeline. For current shareholders, this is a clear exit strategy at a high valuation, with the added benefit of retaining exposure to early-stage cardiology assets through the SpinCo. For potential investors, while the immediate upside might be limited to the acquisition price if not already factored in, the deal underscores the value of the underlying science, making the SpinCo potentially attractive or indicating a strong market for similar biotech assets.

Keywords

Avidity Biosciences, Novartis, Merger, Acquisition, Spin-Off, AOC platform, Duchenne muscular dystrophy, Myotonic dystrophy type 1, FSHD, Precision cardiology, Biotechnology, Pharmaceuticals, SEC filing, Proxy statement